BR112015006755A2 - métodos para alívio de sintomas de esclerose múltipla baseados em composições contendo apoaequorina - Google Patents

métodos para alívio de sintomas de esclerose múltipla baseados em composições contendo apoaequorina

Info

Publication number
BR112015006755A2
BR112015006755A2 BR112015006755A BR112015006755A BR112015006755A2 BR 112015006755 A2 BR112015006755 A2 BR 112015006755A2 BR 112015006755 A BR112015006755 A BR 112015006755A BR 112015006755 A BR112015006755 A BR 112015006755A BR 112015006755 A2 BR112015006755 A2 BR 112015006755A2
Authority
BR
Brazil
Prior art keywords
apoaequorin
methods
multiple sclerosis
containing compositions
symptoms based
Prior art date
Application number
BR112015006755A
Other languages
English (en)
Inventor
Y Underwood Mark
Original Assignee
Quincy Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience Llc filed Critical Quincy Bioscience Llc
Publication of BR112015006755A2 publication Critical patent/BR112015006755A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • C12Y113/12005—Renilla-luciferin 2-monooxygenase (1.13.12.5), i.e. renilla-luciferase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)

Abstract

resumo patente de invenção: "métodos para alívio de sintomas de esclerose múltipla baseados em composições contendo apoaequorina". a presente invenção refere-se a métodos para aliviar sintomas relacionados com esclerose múltipla por administração de apoaequorina, que são fornecidos por esta invenção. tais sintomas incluem, por exemplo, qualidade de sono, qualidade de energia, qualidade de humor, qualidade de memória ou dor.
BR112015006755A 2012-09-27 2013-09-27 métodos para alívio de sintomas de esclerose múltipla baseados em composições contendo apoaequorina BR112015006755A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261706615P 2012-09-27 2012-09-27
PCT/US2013/062268 WO2014052807A1 (en) 2012-09-27 2013-09-27 Methods for alleviating symptoms of multiple sclerosis based on apoaequorin-containing compositions

Publications (1)

Publication Number Publication Date
BR112015006755A2 true BR112015006755A2 (pt) 2017-07-04

Family

ID=50389004

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015006755A BR112015006755A2 (pt) 2012-09-27 2013-09-27 métodos para alívio de sintomas de esclerose múltipla baseados em composições contendo apoaequorina

Country Status (24)

Country Link
US (1) US20150246101A1 (pt)
EP (1) EP2900253B1 (pt)
JP (1) JP6607782B2 (pt)
KR (1) KR102195761B1 (pt)
CN (1) CN104684566A (pt)
AU (1) AU2013323288B2 (pt)
BR (1) BR112015006755A2 (pt)
CA (1) CA2886097C (pt)
CY (1) CY1121216T1 (pt)
DK (1) DK2900253T3 (pt)
ES (1) ES2710937T3 (pt)
HK (1) HK1210698A1 (pt)
HR (1) HRP20190182T1 (pt)
HU (1) HUE041492T2 (pt)
IL (1) IL237751B (pt)
LT (1) LT2900253T (pt)
MX (1) MX369389B (pt)
PL (1) PL2900253T3 (pt)
PT (1) PT2900253T (pt)
SG (1) SG11201502418VA (pt)
SI (1) SI2900253T1 (pt)
TR (1) TR201818988T4 (pt)
WO (1) WO2014052807A1 (pt)
ZA (1) ZA201502849B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40959A (fr) * 2014-11-11 2017-09-19 Quincy Bioscience Llc Compositions contenant de l'apoaéquorine et leurs procédés d'utilisation pour traiter l'inflammation neuronale
US20190365854A1 (en) * 2016-09-23 2019-12-05 Quincy Bioscience, Llc Apoaequorin and vitamin d-containing compositions and methods of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2157979T3 (en) * 2007-05-24 2018-08-27 Calcimedica Inc CALCIUM CHANNEL PROTEINS AND APPLICATIONS THEREOF
MX2010009753A (es) * 2008-03-11 2010-09-30 Quincy Bioscience Llc Composiciones que contienen apoaecuorina y metodos de uso de las mismas.
AU2009279937A1 (en) * 2008-08-06 2010-02-11 Merck Sharp & Dohme Corp. Substituted dihydroisoquinolinone and isoquinolinedione derivatives as calcium channel blockers
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin
WO2012022740A1 (en) * 2010-08-18 2012-02-23 Merck Serono S.A. Combination treatment of multiple sclerosis

Also Published As

Publication number Publication date
EP2900253B1 (en) 2018-11-14
MX2015003879A (es) 2015-07-17
HRP20190182T1 (hr) 2019-03-22
JP6607782B2 (ja) 2019-11-20
KR102195761B1 (ko) 2020-12-28
WO2014052807A1 (en) 2014-04-03
AU2013323288A1 (en) 2015-05-07
EP2900253A1 (en) 2015-08-05
TR201818988T4 (tr) 2019-01-21
ES2710937T3 (es) 2019-04-29
CA2886097A1 (en) 2014-04-03
CA2886097C (en) 2020-07-14
SI2900253T1 (sl) 2019-03-29
IL237751B (en) 2020-10-29
ZA201502849B (en) 2016-07-27
PT2900253T (pt) 2019-02-25
HK1210698A1 (en) 2016-05-06
LT2900253T (lt) 2019-03-25
US20150246101A1 (en) 2015-09-03
PL2900253T3 (pl) 2019-04-30
IL237751A0 (en) 2015-05-31
CY1121216T1 (el) 2020-05-29
CN104684566A (zh) 2015-06-03
MX369389B (es) 2019-11-07
KR20150060954A (ko) 2015-06-03
JP2015532288A (ja) 2015-11-09
AU2013323288B2 (en) 2017-12-07
DK2900253T3 (en) 2019-02-18
HUE041492T2 (hu) 2019-05-28
EP2900253A4 (en) 2016-06-15
SG11201502418VA (en) 2015-04-29

Similar Documents

Publication Publication Date Title
BR112014003477A2 (pt) composições imunoterapêuticas de levedura-muc1 e usos das mesmas
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
BR112012024963A2 (pt) organossilicones
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
BR112015000399A2 (pt) derivados de pirazolil pirimidina
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
BRPI0813966A8 (pt) Usos de mdl-1
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
CY1114960T1 (el) Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου
BR112014009866A2 (pt) formulações de anticorpos e métodos
IN2012DN02471A (pt)
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
CL2013000310A1 (es) Compuestos derivados de tetrahidrofuranilo disustituidos y sus sales, como antagonistas del receptor b1 de bradiquinina; medicamento que contiene a dichos compuestos; su procedimiento de preparacion, util para el tratamiento agudo o profilactico de dolores agudos, osteoartritis, asma, alergias, entre otras enfermedades.
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
MX343517B (es) 2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide.
UA110332C2 (en) Use of 2,3-dihydroxypropyldodecanoate for treatment of seborrhea
MX2010004814A (es) Metodos para tratar esclerodermia.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]